论文部分内容阅读
目的评价新辅助化疗(CS组)与单纯手术(S组)治疗食管癌的疗效与安全性。方法检索PubMed、万方等数据库的关于食管癌的英文和中文随机对照试验(RCT)文献,按入选标准纳入研究。数据分析采用stata v.10.0软件,检验异质性,选择相应效应模型合并统计量。通过漏斗图等评定有无发表偏倚。结果共10项RCT(2 080例食管癌患者)入选。与S组比较,CS组未明显延长食管癌生存期,合并HR为0.95(95%CI 0.86-1.04),其中新辅助化疗有效的患者较单纯手术者生存期有改善,HR为0.58(95%CI 0.47-0.72);CS组术后并发症与S组相比较无明显差异,OR为1.05(95%CI 0.87-1.27)。结论与单纯手术相比较,新辅助化疗未增加术后并发症的发生率,且有效的新辅助化疗能延长食管癌患者的生存期。
Objective To evaluate the efficacy and safety of neoadjuvant chemotherapy (CS group) and simple surgery (S group) in the treatment of esophageal cancer. Methods PubMed, Wanfang and other databases of English and Chinese randomized controlled trials (RCT) on esophageal cancer were included in the study according to inclusion criteria. Data analysis using stata v.10.0 software, testing heterogeneity, select the corresponding effect model merged statistics. Evaluate the presence or absence of publication by funnel charts. Results A total of 10 RCTs (2,080 patients with esophageal cancer) were enrolled. Compared with group S, group CS did not significantly prolong the survival of esophageal cancer, with a combined HR of 0.95 (95% CI 0.86-1.04). Patients with neoadjuvant chemotherapy had better survival than those with simple surgery, HR was 0.58 (95% CI 0.47-0.72). There was no significant difference in postoperative complications between CS group and S group (OR = 1.05, 95% CI 0.87-1.27). Conclusion Compared with simple operation, neoadjuvant chemotherapy does not increase the incidence of postoperative complications, and effective neoadjuvant chemotherapy can extend the survival of esophageal cancer patients.